Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis

Giancarlo Comi, Hans Peter Hartung, Nuwan C. Kurukulasuriya, Steven J. Greenberg, Matthew Scaramozza

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Introduction: Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system leading to progressive neurodegeneration and disability. Until 2010, all approved disease-modifying drugs for MS required parenteral administration, which is associated with suboptimal adherence. It was anticipated that new approaches to treatment, including oral agents such as cladribine tablets, may improve adherence. In 2011, the development of cladribine tablets was stopped following negative feedback from the EMA and FDA. Areas covered: This article provides an overview of the chemistry, mechanism of action and pharmacological properties of cladribine tablets therapy, and highlights the rationale for its development as an oral treatment for MS. Key efficacy and safety data from the pivotal Phase III CLARITY study are presented, providing context for the opinion received from the regulatory agencies. Expert opinion: Despite the promising efficacy data observed in the cladribine tablets clinical trial program, regulatory agencies identified a potential risk of increased malignancies, and raised concerns about the implications of sustained lymphocyte depletion. Following the feedback received from the regulatory agencies, Merck Serono made the decision to withdraw the agent from the regulatory approval process. The experience gained will benefit other research efforts to address the outstanding unmet treatment needs of patients with relapsing MS.

Original languageEnglish
Pages (from-to)123-136
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Cladribine
Relapsing-Remitting Multiple Sclerosis
Tablets
Multiple Sclerosis
Molecular Mechanisms of Pharmacological Action
Lymphocyte Depletion
Immune System Diseases
Expert Testimony
Therapeutics
Central Nervous System
Clinical Trials
Safety
Research
Pharmaceutical Preparations
Neoplasms

Keywords

  • Cladribine tablets
  • CLARITY study
  • Multiple sclerosis
  • Oral therapy
  • Risk-benefit

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. / Comi, Giancarlo; Hartung, Hans Peter; Kurukulasuriya, Nuwan C.; Greenberg, Steven J.; Scaramozza, Matthew.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 1, 01.2013, p. 123-136.

Research output: Contribution to journalArticle

Comi, Giancarlo ; Hartung, Hans Peter ; Kurukulasuriya, Nuwan C. ; Greenberg, Steven J. ; Scaramozza, Matthew. / Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. In: Expert Opinion on Pharmacotherapy. 2013 ; Vol. 14, No. 1. pp. 123-136.
@article{8c2a69cd89f845679b5a06a9aac037d8,
title = "Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis",
abstract = "Introduction: Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system leading to progressive neurodegeneration and disability. Until 2010, all approved disease-modifying drugs for MS required parenteral administration, which is associated with suboptimal adherence. It was anticipated that new approaches to treatment, including oral agents such as cladribine tablets, may improve adherence. In 2011, the development of cladribine tablets was stopped following negative feedback from the EMA and FDA. Areas covered: This article provides an overview of the chemistry, mechanism of action and pharmacological properties of cladribine tablets therapy, and highlights the rationale for its development as an oral treatment for MS. Key efficacy and safety data from the pivotal Phase III CLARITY study are presented, providing context for the opinion received from the regulatory agencies. Expert opinion: Despite the promising efficacy data observed in the cladribine tablets clinical trial program, regulatory agencies identified a potential risk of increased malignancies, and raised concerns about the implications of sustained lymphocyte depletion. Following the feedback received from the regulatory agencies, Merck Serono made the decision to withdraw the agent from the regulatory approval process. The experience gained will benefit other research efforts to address the outstanding unmet treatment needs of patients with relapsing MS.",
keywords = "Cladribine tablets, CLARITY study, Multiple sclerosis, Oral therapy, Risk-benefit",
author = "Giancarlo Comi and Hartung, {Hans Peter} and Kurukulasuriya, {Nuwan C.} and Greenberg, {Steven J.} and Matthew Scaramozza",
year = "2013",
month = "1",
doi = "10.1517/14656566.2013.754012",
language = "English",
volume = "14",
pages = "123--136",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis

AU - Comi, Giancarlo

AU - Hartung, Hans Peter

AU - Kurukulasuriya, Nuwan C.

AU - Greenberg, Steven J.

AU - Scaramozza, Matthew

PY - 2013/1

Y1 - 2013/1

N2 - Introduction: Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system leading to progressive neurodegeneration and disability. Until 2010, all approved disease-modifying drugs for MS required parenteral administration, which is associated with suboptimal adherence. It was anticipated that new approaches to treatment, including oral agents such as cladribine tablets, may improve adherence. In 2011, the development of cladribine tablets was stopped following negative feedback from the EMA and FDA. Areas covered: This article provides an overview of the chemistry, mechanism of action and pharmacological properties of cladribine tablets therapy, and highlights the rationale for its development as an oral treatment for MS. Key efficacy and safety data from the pivotal Phase III CLARITY study are presented, providing context for the opinion received from the regulatory agencies. Expert opinion: Despite the promising efficacy data observed in the cladribine tablets clinical trial program, regulatory agencies identified a potential risk of increased malignancies, and raised concerns about the implications of sustained lymphocyte depletion. Following the feedback received from the regulatory agencies, Merck Serono made the decision to withdraw the agent from the regulatory approval process. The experience gained will benefit other research efforts to address the outstanding unmet treatment needs of patients with relapsing MS.

AB - Introduction: Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system leading to progressive neurodegeneration and disability. Until 2010, all approved disease-modifying drugs for MS required parenteral administration, which is associated with suboptimal adherence. It was anticipated that new approaches to treatment, including oral agents such as cladribine tablets, may improve adherence. In 2011, the development of cladribine tablets was stopped following negative feedback from the EMA and FDA. Areas covered: This article provides an overview of the chemistry, mechanism of action and pharmacological properties of cladribine tablets therapy, and highlights the rationale for its development as an oral treatment for MS. Key efficacy and safety data from the pivotal Phase III CLARITY study are presented, providing context for the opinion received from the regulatory agencies. Expert opinion: Despite the promising efficacy data observed in the cladribine tablets clinical trial program, regulatory agencies identified a potential risk of increased malignancies, and raised concerns about the implications of sustained lymphocyte depletion. Following the feedback received from the regulatory agencies, Merck Serono made the decision to withdraw the agent from the regulatory approval process. The experience gained will benefit other research efforts to address the outstanding unmet treatment needs of patients with relapsing MS.

KW - Cladribine tablets

KW - CLARITY study

KW - Multiple sclerosis

KW - Oral therapy

KW - Risk-benefit

UR - http://www.scopus.com/inward/record.url?scp=84871586750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871586750&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.754012

DO - 10.1517/14656566.2013.754012

M3 - Article

C2 - 23256518

AN - SCOPUS:84871586750

VL - 14

SP - 123

EP - 136

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -